Imcivree (Setmelanotide) for Obesity | MyObesityTeam

Connect with others who understand.

sign up Log in
About MyObesityTeam
Powered By

Imcivree is a prescription drug approved by the U.S. Food and Drug Administration (FDA) for weight management in adults and children 6 years old and up who have obesity. Specifically, this drug is approved only for people with obesity due to the following conditions:

  • Pro-opiomelanocortin (POMC)

  • Proprotein convertase subtilisin/kexin type 1 (PCSK1)

  • Leptin receptor (LEPR) deficiency

  • Bardet-Biedl syndrome (BBS)
  • These conditions must be diagnosed by an FDA-approved genetic test showing genes that are pathogenic, likely pathogenic, or of uncertain significance.

    Imcivree is also referred to by its drug name, setmelanotide.

    Imcivree is a melanocortin receptor agonist. It works by interacting with the parts of the brain that regulate hunger and energy use to decrease appetite and increase energy expenditure. This mechanism of action can help certain people to lose weight and not gain it back again.

    How do I take it?
    Prescribing information states that Imcivree is available as a subcutaneous (under the skin) injection.

    Side effects
    The FDA-approved label for Imcivree lists common side effects including skin hyperpigmentation, nausea, vomiting, abdominal pain, diarrhea, headache, depression, injection site reaction, and spontaneous penile erection.

    For more details about this treatment, visit:

    FDA Approves First Treatment for Weight Management for People With Certain Rare Genetic Conditions — U.S. Food & Drug Administration

    Setmelanotide Injection — MedlinePlus

    Continue with Facebook
    Continue with Google
    Lock Icon Your privacy is our priority. By continuing, you accept our Terms of use, and our Health Data and Privacy policies.
    Already a Member? Log in